GSK plc 6-K, filed Jul 5, 2022
GSK plc (GSK)
6-K
2022-07-05
For: 2022-07-05
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on July 5, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 5 July 2022, London UK
GSK to disclose discontinued operations from Q2 2022
GSK plc (LSE/NYSE: GSK) will as
a consequence of its proposed demerger of the Consumer Healthcare
business on 18 July 2022 disclose its Q2 2022 results on 27 July
2022 in accordance with the requirements of IFRS 5 - 'Non-current
Assets Held for Sale and Discontinued Operations'. GSK has now
satisfied the
formal criteria for treating Consumer Healthcare as a 'Discontinued
operation' effective from 30 June 2022, accordingly it will no
longer present the Consumer Healthcare business within 'Continuing
operations' and will also disclose the assets and liabilities of
the Consumer Healthcare business as assets and liabilities held for
sale/distribution. The GSK Group ('Group') will continue to
consolidate the business for reporting purposes until the demerger
of the Consumer Healthcare business has completed. Details of the
demerger are included in the published Prospectus and Circular for
the proposed demerger of the Consumer Healthcare business to form
Haleon plc ('Haleon').
Requirements of IFRS 5 - 'Non-current Assets Held for Sale and
Discontinued Operations'
GSK has satisfied the requirements under IFRS 5 to treat the
Consumer Healthcare business as a 'disposal group' effective from
30 June 2022, as
it is expected that the carrying amount of the disposal group will
be recovered principally through disposal and a distribution, it is
available for distribution in its present condition (subject
only to the steps to be completed that are usual and customary for
the demerger of a business) and it is considered highly
probable (the expected date of the demerger being 18 July
2022).
As a consequence of meeting these formal criteria, the Consumer
Healthcare business will no longer be presented as 'Continuing
operations', which will result in the following changes to the
presentation of the Q2 2022 results on 27 July 2022:
● Turnover, cost of sales, SG&A expenses,
research and development expenses, royalty income, other income and
expenses, operating profit, profit before taxation, profit after
taxation from continuing operations and Adjusted[1] results
of the Group will be presented on the basis of the 'Continuing
operations' of the Group, with the component of the post-tax Group
results attributable to 'Discontinued operations' presented as a
single line item in the Income Statement. The Total post-tax
results of the Group will include 'Continuing' and 'Discontinued
operations'.
● The earnings per share of the Group will be
presented separately between the earnings per share attributable to
'Continuing operations' and earnings per share attributable to
'Discontinued operations'. Adjusted
earnings per share will only be presented for 'Continuing
operations'. Earnings
per share for Q2 2022 and for prior periods will
be adjusted to reflect the impact of the GSK share consolidation
expected to take place following the demerger but prior to the Q2
results announcement on 27 July 2022. The earnings per share
figures presented below are based on the current pre-consolidation
GSK share capital structure.
● Comparative income statement information will be
re-presented on a consistent basis;
● GSK will no longer present a Consumer Healthcare
segment and those items previously reported within the Consumer
Healthcare segment that do not form part of the 'Discontinued
operations' of the Group will be shown as part of 'Continuing
operations' and reported within either the Commercial Operations
segment or Corporate and unallocated costs, as
appropriate;
● Disclosure of the Total turnover, expenses,
pre-tax profit and tax expense of the 'Discontinued operations'
will be reported as an additional disclosure on a Total basis
only;
● The respective totals of the net cash inflow from
operations, the net cash inflow from operating activities, the net
cash flow from investing activities and the net cash flow from
financing activities will be shown split between 'Continuing
operations' and 'Discontinued operations'. Free cash
flow[2] will
be presented only for 'Continuing operations';
● The assets and liabilities of the Consumer
Healthcare 'disposal group' will be presented on the face of the
Group balance sheet as assets held for sale/distribution and
liabilities held for sale/ distribution respectively as current
assets and liabilities. Analysis of the main categories of assets
and liabilities reported as assets and liabilities held for
sale/distribution will be presented as a note to the financial
statements.
Impact of the application of the requirements of IFRS
5
The application of the requirements of IFRS 5 has no impact on the
total post-tax results of the Group in the presentation of the
restated historical information. However, as a result of the
reclassification of the assets and liabilities of the Consumer
Healthcare business (the 'disposal group') to assets and
liabilities held for sale/ distribution with effect from 30 June
2022, they are held at the lower of carrying amount and fair value
less costs to distribute and from that point onwards, depreciation
and amortisation ceases on those tangible and intangible assets
reclassified as part of the assets held for
sale/distribution.
The application of IFRS 5 also has no impact on the total reported
cash flows of the Group, although under the requirements of IFRS 5,
the total for each category of the reported cash flows of the Group
(net cash inflow from operations, cash flow from operating
activities, cash flow from investing activities and cash flow from
financing activities) should be presented split between
'Continuing' and 'Discontinued operations'.
As a result of the presentational changes, cash generated from
operations for the full year 2021 was £7,249 million for
'Continuing operations' (Q1 2021: £406 million; Q1 2022:
£2,353 million) and cash generated from operations was
£1,994 million for 'Discontinued operations' (Q1 2021:
£80 million; Q1 2022: £402 million).
Net cash inflow from continuing operating
activities for the
full year 2021 was £6,277 million (Q1 2021: £316 million;
Q1 2022: £2,207 million) and net operating cash flows
attributable to discontinued
activities was
£1,675 million (Q1 2021: £15 million; Q1 2022: £335
million).
Net increase/(decrease) in cash and bank overdrafts from
'Continuing operations' for the full year 2021 was £(2,505)
million (Q1 2021: £(900) million; Q1 2022: £283 million)
and net increase/(decrease) in cash and bank overdrafts
attributable to 'Discontinued operations' was £1,091 million
(Q1 2021: £(193) million; Q1 2022: £6,639
million).
Impact on the Group's reportable segments
The Group presents its segmental results based on the Adjusted
results of the Group from
'Continuing operations' and will therefore exclude the Consumer
Healthcare business from Q2 2022. As a result, the Group will no
longer report a Consumer Healthcare segment. The Group will
continue to report the results of the Commercial Operations segment
and the Research and Development segment.
As a result of reporting the results of the continuing operations
of GSK and no longer reporting the Consumer Healthcare segment, the
results of the Commercial Operations segment and those costs shown
under Corporate and unallocated costs for prior periods have been
revised. This reflects the following principal
changes:
● Certain revenues and costs reported within the
Consumer Healthcare segment will be split between the 'Continuing
operations' and 'Discontinued operations' of the Group income
statement, primarily reflecting contract manufacturing that will
continue to be performed by GSK on behalf of the Haleon group after
the demerger. The value of the sales and related costs that will be
included in the 'Continuing operations' of the Group will be
reported as part of the Commercial Operations
segment;
● The Consumer Healthcare segment included some
markets that were not within the perimeter of the Consumer
Healthcare joint venture with Pfizer and will not be part of the
Consumer Healthcare business to be demerged. These will be reported
as part of the Commercial Operations segment.
● Corporate costs that were allocated to the
Consumer Healthcare segment and will continue to be incurred by GSK
after the demerger. These costs will be reported within the
Corporate and unallocated costs as 'Continuing operations'.
Corporate costs incurred by GSK in prior periods on behalf of
Consumer Healthcare that have been transferred to Haleon group
companies ahead of the demerger will be reported as part of
'Discontinued operations'.
The impact of these 'Continuing operations' sales and costs
previously reported in the Consumer Healthcare segment and that do
not form part of the 'Discontinued operations' do not materially
change the reported performance of the Commercial Operations
segment.
The tables below set out the revised format for reporting the
income statement under the requirements of IFRS 5 that will be
applied from the Q2 2022 results, as applied to the Q1 2021, Q2
2021, Q3 2021, Q4 2021 and full year 2021 and the Q1 2022
results.
An Microsoft Excel version of this data is available
on www.gsk.com.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madeleine
Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
This Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The information for 2021 and 2020 has
been derived from the full Group accounts published in the Annual
Report 2021.
Results by quarter for 2021, full year 2021 and Q1 2022 results
presented under IFRS 5
|
|
|
|
Total Results
|
|
|
|
Q1
2021
£m
|
|
Q2
2021
£m
|
|
Q3
2021
£m
|
|
Q4
2021
£m
|
|
Full
Year
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
5,155
|
|
5,838
|
|
6,627
|
|
7,076
|
|
24,696
|
|
7,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(1,654)
|
|
(1,708)
|
|
(2,016)
|
|
(2,785)
|
|
(8,163)
|
|
(2,717)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
3,501
|
|
4,130
|
|
4,611
|
|
4,291
|
|
16,533
|
|
4,473
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general
and administration
|
(1,509)
|
|
(1,689)
|
|
(1,679)
|
|
(2,193)
|
|
(7,070)
|
|
(1,812)
|
|
Research
and development
|
(1,060)
|
|
(1,167)
|
|
(1,416)
|
|
(1,376)
|
|
(5,019)
|
|
(1,103)
|
|
Royalty
income
|
88
|
|
77
|
|
115
|
|
137
|
|
417
|
|
138
|
|
Other
operating income / (expense)
|
190
|
|
(76)
|
|
(251)
|
|
(368)
|
|
(505)
|
|
592
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
1,210
|
|
1,275
|
|
1,380
|
|
491
|
|
4,356
|
|
2,288
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
6
|
|
4
|
|
3
|
|
1
|
|
14
|
|
8
|
|
Finance
costs
|
(198)
|
|
(189)
|
|
(195)
|
|
(187)
|
|
(769)
|
|
(205)
|
|
Loss on
disposal of interests in associates
|
-
|
|
(36)
|
|
-
|
|
-
|
|
(36)
|
|
-
|
|
Share
of after tax profits of associates and joint ventures
|
16
|
|
16
|
|
3
|
|
(2)
|
|
33
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
1,034
|
|
1,070
|
|
1,191
|
|
303
|
|
3,598
|
|
2,090
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(155)
|
|
201
|
|
(246)
|
|
117
|
|
(83)
|
|
(327)
|
|
Tax rate %
|
15.0%
|
|
(18.8%)
|
|
20.7%
|
|
(38.6%)
|
|
2.3%
|
|
15.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
after tax from continuing operations
|
879
|
|
1,271
|
|
945
|
|
420
|
|
3,515
|
|
1,763
|
|
Profit
after tax from discontinued operations
|
381
|
|
267
|
|
423
|
|
510
|
|
1,581
|
|
404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
after tax for the period
|
1,260
|
|
1,538
|
|
1,368
|
|
930
|
|
5,096
|
|
2,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
(Loss) attributable to non-controlling interests from continuing
operations
|
80
|
|
57
|
|
69
|
|
(6)
|
|
200
|
|
275
|
|
Profit
attributable to shareholders from continuing
operations
|
799
|
|
1,214
|
|
876
|
|
426
|
|
3,315
|
|
1,488
|
|
Profit
attributable to non-controlling interests from discontinued
operations
|
107
|
|
86
|
|
131
|
|
187
|
|
511
|
|
90
|
|
Profit
attributable to shareholders from discontinued
operations
|
274
|
|
181
|
|
292
|
|
323
|
|
1,070
|
|
314
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
profit attributable to non-controlling interests
|
187
|
|
143
|
|
200
|
|
181
|
|
711
|
|
365
|
|
Total
profit attributable to shareholders
|
1,073
|
|
1,395
|
|
1,168
|
|
749
|
|
4,385
|
|
1,802
|
|
|
1,260
|
|
1,538
|
|
1,368
|
|
930
|
|
5,096
|
|
2,167
|
|
Earnings
per share from continuing operations
|
16.0p
|
|
24.3p
|
|
17.6p
|
|
8.4p
|
|
66.3p
|
|
29.7p
|
|
Earnings
per share from discontinued operations
|
5.5p
|
|
3.6p
|
|
5.7p
|
|
6.6p
|
|
21.3p
|
|
6.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share[3]
|
21.5p
|
|
27.9p
|
|
23.3p
|
|
15.0p
|
|
87.6p
|
|
35.9p
|
|
Reconciliation of Total Results from Continuing operations to
Adjusted Results from Continuing operations
|
||||||||||||
|
|
Q1
2021
£m
|
|
Q2
2021
£m
|
|
Q3
2021
£m
|
|
Q4
2021
£m
|
|
Full
Year
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Operating profit from continuing operations
|
1,210
|
|
1,275
|
|
1,380
|
|
491
|
|
4,356
|
|
2,288
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible
amortisation
|
191
|
|
186
|
|
190
|
|
194
|
|
761
|
|
186
|
|
|
Intangible
impairment
|
13
|
|
7
|
|
264
|
|
62
|
|
346
|
|
(16)
|
|
|
Major
restructuring
|
66
|
|
102
|
|
97
|
|
159
|
|
424
|
|
51
|
|
|
Transaction
related
|
116
|
|
130
|
|
290
|
|
604
|
|
1,140
|
|
347
|
|
|
Divestments,
significant legal and other items
|
(271)
|
|
(59)
|
|
(12)
|
|
(193)
|
|
(535)
|
|
(912)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Operating
profit from continuing operations
|
1,325
|
|
1,641
|
|
2,209
|
|
1,317
|
|
6,492
|
|
1,944
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Earnings per share from continuing operations3
|
16.0p
|
|
24.3p
|
|
17.6p
|
|
8.4p
|
|
66.3p
|
|
29.7p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible
amortisation
|
3.1p
|
|
3.0p
|
|
3.1p
|
|
3.0p
|
|
12.2p
|
|
3.0p
|
|
|
Intangible
impairment
|
0.2p
|
|
0.1p
|
|
4.0p
|
|
1.0p
|
|
5.3p
|
|
(0.2)p
|
|
|
Major
restructuring
|
1.1p
|
|
1.6p
|
|
1.5p
|
|
2.7p
|
|
6.9p
|
|
0.8p
|
|
|
Transaction
related
|
1.1p
|
|
1.1p
|
|
4.0p
|
|
8.2p
|
|
14.4p
|
|
8.1p
|
|
|
Divestments,
significant legal and other items
|
(4.5)p
|
|
(7.5)p
|
|
(0.3)p
|
|
(4.5)p
|
|
(16.8)p
|
|
(15.5)p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Earnings
per share from continuing operations3
|
16.9p
|
|
22.6p
|
|
29.9p
|
|
18.8p
|
|
88.3p
|
|
25.8p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted result from continuing operations
Adjusted
results are from continuing operations and exclude the Consumer
Healthcare business.
|
||||||||||||
|
|
Q1
2021
£m
|
|
Q2
2021
£m
|
|
Q3
2021
£m
|
|
Q4
2021
£m
|
|
Full
Year
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
5,155
|
|
5,838
|
|
6,627
|
|
7,076
|
|
24,696
|
|
7,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(1,435)
|
|
(1,522)
|
|
(1,797)
|
|
(2,592)
|
|
(7,346)
|
|
(2,527)
|
|
|
Selling, general
and administration
|
(1,462)
|
|
(1,646)
|
|
(1,623)
|
|
(2,018)
|
|
(6,749)
|
|
(1,769)
|
|
|
Research
and development
|
(1,021)
|
|
(1,107)
|
|
(1,112)
|
|
(1,285)
|
|
(4,525)
|
|
(1,088)
|
|
|
Royalty
income
|
88
|
|
78
|
|
114
|
|
136
|
|
416
|
|
138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
Operating profit
|
1,325
|
|
1,641
|
|
2,209
|
|
1,317
|
|
6,492
|
|
1,944
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(190)
|
|
(185)
|
|
(190)
|
|
(186)
|
|
(751)
|
|
(197)
|
|
|
Share
of after tax profits of associates and joint ventures
|
16
|
|
16
|
|
3
|
|
(2)
|
|
33
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before taxation
|
1,151
|
|
1,472
|
|
2,022
|
|
1,129
|
|
5,774
|
|
1,746
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(195)
|
|
(244)
|
|
(402)
|
|
(77)
|
|
(918)
|
|
(291)
|
|
|
Tax rate %
|
16.9%
|
|
16.6%
|
|
19.9%
|
|
6.8%
|
|
15.9%
|
|
16.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted profit
after taxation
|
956
|
|
1,228
|
|
1,620
|
|
1,052
|
|
4,856
|
|
1,455
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted profit
attributable to non-controlling interests
|
112
|
|
99
|
|
121
|
|
109
|
|
441
|
|
161
|
|
|
Adjusted profit
attributable to shareholders
|
844
|
|
1,129
|
|
1,499
|
|
943
|
|
4,415
|
|
1,294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings per share3
|
16.9p
|
|
22.6p
|
|
29.9p
|
|
18.8p
|
|
88.2p
|
|
25.8p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of Covid solutions[4]
|
(0.2)p
|
|
3.8p
|
|
1.5p
|
|
3.8p
|
|
8.8p
|
|
3.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment (continuing operations)
|
Operating
profits by segment are from continuing operations and exclude the
Consumer Healthcare business.
|
||||||||||||
|
|
Q1
2021
£m
|
|
Q2
2021
£m
|
|
Q3
2021
£m
|
|
Q4
2021
£m
|
|
Full
Year
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
2,446
|
|
2,872
|
|
3,461
|
|
2,703
|
|
11,482
|
|
3,120
|
|
|
Research
and Development
|
(1,030)
|
|
(1,118)
|
|
(1,139)
|
|
(1,281)
|
|
(4,568)
|
|
(1,095)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
1,416
|
|
1,754
|
|
2,322
|
|
1,422
|
|
6,914
|
|
2,025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate
& other unallocated costs
|
(91)
|
|
(113)
|
|
(113)
|
|
(105)
|
|
(422)
|
|
(81)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
1,325
|
|
1,641
|
|
2,209
|
|
1,317
|
|
6,492
|
|
1,944
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of Covid solutions
|
(12)
|
|
233
|
|
97
|
|
214
|
|
532
|
|
194
|
|
Commercial operations turnover
|
|
Q1
2021
£m
|
|
Q2
2021
£m
|
|
Q3
2021
£m
|
|
Q4
2021
£m
|
|
Full
Year
£m
|
|
Q1
2022
£m
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Specialty
|
1,575
|
|
1,879
|
|
2,019
|
|
2,778
|
|
8,251
|
|
3,135
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Vaccines
|
1,224
|
|
1,571
|
|
2,174
|
|
1,809
|
|
6,778
|
|
1,669
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Respiratory
|
1,492
|
|
1,514
|
|
1,492
|
|
1,550
|
|
6,048
|
|
1,535
|
||||||||
|
Other
General Medicines
|
864
|
|
874
|
|
942
|
|
939
|
|
3,619
|
|
851
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
General
Medicines
|
2,356
|
|
2,388
|
|
2,434
|
|
2,489
|
|
9,667
|
|
2,386
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Total
Commercial Operations
|
5,155
|
|
5,838
|
|
6,627
|
|
7,076
|
|
24,696
|
|
7,190
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
US
|
2,218
|
|
2,782
|
|
3,390
|
|
3,524
|
|
11,914
|
|
3,586
|
||||||||
|
Europe
|
1,257
|
|
1,260
|
|
1,333
|
|
1,520
|
|
5,370
|
|
1,660
|
||||||||
|
International
|
1,680
|
|
1,796
|
|
1,904
|
|
2,032
|
|
7,412
|
|
1,944
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Total
Commercial Operations
|
5,155
|
|
5,838
|
|
6,627
|
|
7,076
|
|
24,696
|
|
7,190
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Impact of Covid solutions
|
-
|
|
276
|
|
209
|
|
920
|
|
1,405
|
|
1,307
|
||||||||
[1] Total and
Adjusted Results - Adjusted
results are a non-IFRS measure that may be considered in addition
to, but not as a substitute for, or superior to, information
presented in accordance with IFRS. Adjusted
results exclude the profits from discontinued operations from the
Consumer Healthcare business and the items defined on page 20 of
the Q1 2022 results announcement in relation to our continuing
operations. The Q1 2022 results announcement is available
at www.gsk.com
[2] Free
cash flow -
Free cash flow is a non-IFRS measure that may be considered in
addition to, but not as a substitute for, or superior to,
information presented in accordance with IFRS. Free
cash flow is defined on page 42 of the Q1 2022 results
announcement. The Q1 2022 results announcement is available
at www.gsk.com
[3] Earnings
per share for Q2 2022 and for prior periods will be adjusted to
reflect the impact of the GSK share consolidation expected to take
place following the demerger (the earnings per share figures
presented are based on the current pre-consolidation GSK share
capital structure).
[4] COVID-19
solutions include the sales of pandemic adjuvant and other COVID-19
solutions including vaccine manufacturing and Xevudy and the
associated costs but does not include reinvestment in R&D. This
categorisation is used by management and we believe is helpful to
investors through providing clarity on the results of the Group by
showing the contribution to growth from COVID-19
solutions.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
05, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|